Novo Nordisk 2012 net profit leaps 25% and sales rise 18%

31 January 2013

Denmark-based insulin giant Novo Nordisk (NOV: N) saw its shares rise 1.6% to 1,037 kroner in early trading this morning, when the company posted a strong set of financials for full year 2012, with sales rising 18% (12% in local currencies) to 78.0 billion Danish kroner ($14.08 billion).

Reported operating profit increased by 32% to 29.5 billion kroner including a 1.7 percentage points improvement in the gross margin. Measured in local currencies, operating profit increased by 20%. Net profit increased by 25% to DKK 21.4 billion kroner. Earnings per share (diluted) increased by 30% to DKK 38.85.

Fourth-quarter net income rose 23% to 5.76 billion kroner, beating the 5.34 billion-kroner average estimates of analysts compiled by Bloomberg

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK